The European Medicines Agency has announced the start of a safety review of the Novartis treatment for multiple sclerosis, Gilenya (fingolimod), less than a year after the drug was authorised for marketing in the European Union. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News